In the fourth quarter of fiscal year 2026, Dr Reddy's Laboratories experienced a sharp 86.2% year-on-year decrease in consolidated net profit, which fell to ₹220.1 crore. Despite this substantial decline in profitability, the company's board of directors has proposed a final dividend of ₹8 per share, with a face value of ₹1 each, for the fiscal year 2026. This dividend recommendation underscores Dr Reddy's commitment to maintaining shareholder value amid challenging market conditions. The results highlight the company's current financial performance within the Indian pharmaceutical sector. Dr Reddy's Q4 results 2026: Dr Reddy's Laboratories reported a sharp 86.2% YoY fall in its consolidated net profit to ₹220.1 crore for Q4FY26.